donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ATNX Athenex > Detailed Quotes

ATNX Athenex

0.520
-0.018-3.33%
Close 08/12 16:00 ET
0.530
+0.01+1.92%
Post Mkt Price 08/12 19:59 ET
High
0.565
Open
0.550
Turnover
3.30M
Low
0.515
Pre Close
0.538
Volume
6.18M
Market Cap
63.24M
P/E(TTM)
Loss
52wk High
3.910
Shares
121.61M
P/E(Static)
Loss
52wk Low
0.405
Float Cap
43.58M
Bid/Ask %
-37.14%
Historical High
21.110
Shs Float
83.81M
Volume Ratio
0.62
Historical Low
0.405
Dividend TTM
--
Div Yield TTM
30
P/B
5.31
Dividend LFY
--
Div Yield LFY
5769.23%
Turnover Ratio
7.38%
Amplitude
9.28%
Avg Price
0.534
Lot Size
1
Float Cap
43.58M
Bid/Ask %
-37.14%
Historical High
21.110
Shs Float
83.81M
Volume Ratio
0.62
Historical Low
0.405
Dividend TTM
--
P/B
5.31
Dividend LFY
--
Turnover Ratio
7.38%
Amplitude
9.28%
Avg Price
0.534
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
CEO: Lau F.R.C.P., M.B.B.S., M.D., Ph.D., Yiu-Nam
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...